Arginase II polymorphisms modify the hypotensive responses to propofol by affecting nitric oxide bioavailability (2021)
- Authors:
- USP affiliated authors: PAULA, GUSTAVO HENRIQUE OLIVEIRA DE - FMRP ; PINHEIRO, LUCAS CÉZAR - EERP ; GARCIA, LUIS VICENTE - FMRP ; SANTOS, JOSE EDUARDO TANUS DOS - FMRP ; LACCHINI, RICCARDO - EERP ; LACCHINI, FERNANDA BORCHERS COELI - FCFRP ; FEREZIN, LETÍCIA PERTICARRARA - FMRP ; FERREIRA, GRAZIELE CRISTINA - FMRP ; GARCIA, WAYNICE NEIVA DE PAULA - FMRP
- Unidades: FMRP; EERP; FCFRP
- DOI: 10.1007/s00228-020-03059-9
- Subjects: MEDICAMENTO; POLIMORFISMO; ÓXIDO NÍTRICO; ANESTESIA; PRESSÃO SANGUÍNEA
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: Heidelberg
- Date published: 2021
- Source:
- Título: European Journal of Clinical Pharmacology
- ISSN: 0031-6970
- Volume/Número/Paginação/Ano: v. 77, n. 6, p. 869-877, 2021
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
OLIVEIRA-PAULA, Gustavo Henrique et al. Arginase II polymorphisms modify the hypotensive responses to propofol by affecting nitric oxide bioavailability. European Journal of Clinical Pharmacology, v. 77, n. 6, p. 869-877, 2021Tradução . . Disponível em: https://doi.org/10.1007/s00228-020-03059-9. Acesso em: 02 dez. 2025. -
APA
Oliveira-Paula, G. H., Coeli-Lacchini, F. B., Ferezin, L. P., Ferreira, G. C., Pinheiro, L. C., Garcia, W. N. de P., et al. (2021). Arginase II polymorphisms modify the hypotensive responses to propofol by affecting nitric oxide bioavailability. European Journal of Clinical Pharmacology, 77( 6), 869-877. doi:10.1007/s00228-020-03059-9 -
NLM
Oliveira-Paula GH, Coeli-Lacchini FB, Ferezin LP, Ferreira GC, Pinheiro LC, Garcia WN de P, Garcia LV, Tanus-Santos JE, Lacchini R. Arginase II polymorphisms modify the hypotensive responses to propofol by affecting nitric oxide bioavailability [Internet]. European Journal of Clinical Pharmacology. 2021 ; 77( 6): 869-877.[citado 2025 dez. 02 ] Available from: https://doi.org/10.1007/s00228-020-03059-9 -
Vancouver
Oliveira-Paula GH, Coeli-Lacchini FB, Ferezin LP, Ferreira GC, Pinheiro LC, Garcia WN de P, Garcia LV, Tanus-Santos JE, Lacchini R. Arginase II polymorphisms modify the hypotensive responses to propofol by affecting nitric oxide bioavailability [Internet]. European Journal of Clinical Pharmacology. 2021 ; 77( 6): 869-877.[citado 2025 dez. 02 ] Available from: https://doi.org/10.1007/s00228-020-03059-9 - Gene–gene interactions in the protein kinase C/endothelial nitric oxide synthase axis impact the hypotensive effects of propofol
- TRPA1 polymorphisms modify the hypotensive responses to propofol with no change in nitrite or nitrate levels
- Antioxidant tempol modulates the increases in tissue nitric oxide metabolites concentrations after oral nitrite administration
- Endothelial nitric oxide synthase polymorphisms affect the changes in blood pressure and nitric oxide bioavailability induced by propofol
- Mechanisms impairing blood pressure responses to nitrite and nitrate
- Antiseptic mouthwash inhibits antihypertensive and vascular protective effects of L-arginine
- Angiotensin converting enzyme inhibitors enhance the hypotensive effects of propofol by increasing nitric oxide production
- Association of 11β-hydroxysteroid dehydrogenase type1 (HSD11b1) gene polymorphisms with outcome of antidepressant therapy and suicide attempts
- Lidocaine combined with magnesium sulfate preserved hemodynamic stability during general anesthesia without prolonging neuromuscular blockade: a randomized, double-blind, controlled trial
- Association between endothelial nitric oxide synthase and the renin-angiotensin-aldosterone system polymorphisms, blood pressure and training status in normotensive/pre-hypertension and hypertensive older adults: a pilot study
Informações sobre o DOI: 10.1007/s00228-020-03059-9 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
